Well, there is no requirement that XOMA publish the detailed trial results. Maybe they'll hold off on publication until Gevokizumab is closer to approval in EOH, assuming they decide to pursue the indication further.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”